Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCSF
Dates
study started
estimated completion

Description

Summary

Currently enrolling a total of 12 patients for Phase 2a of the study: 6 patients must have VA of no-better-than hand motion in the study eye, and 6 patients must have VA in the study eye to range from no-worse-than count fingers to 20/200 vision.

Official Title

Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)

Keywords

Advanced Retinitis Pigmentosa gene therapy optogenetics channelrhodopsin retina retinitis pigmentosa Retinitis RST-001

Eligibility

You can join if…

Open to people ages 18 years and up

Participants must meet all of the following criteria.

  1. Age >= 18 years
  2. Signed and dated written informed consent obtained from the patient.
  3. Ability to comply with testing and all protocol tests.

You CAN'T join if...

Any one of the following will exclude patients from being enrolled into the study:

  1. Unable or unwilling to meet requirements of the study;
  2. Participation in a clinical study (ocular or non-ocular) with an investigational drug, agent or therapy in the past six months

Locations

  • University of California, San Francisco- Dept. of Ophthalmology
    San Francisco California 94143 United States
  • Retina Foundation of the Southwest
    Dallas Texas 75231 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Allergan
ID
NCT02556736
Phase
Phase 1/2
Study Type
Interventional
Last Updated